This site is intended for healthcare professionals in the United Kingdom.
CRESEMBA® is indicated in adults for the treatment of
  • -invasive aspergillosis1
  • -mucormycosis in patients for whom amphotericin B is inappropriate1
Consideration should be given to official guidance on the appropriate use of antifungal agents.
For more information on ordering CRESEMBA, click here
 
 
 

dosing and formulation

vial image

vial

Each vial contains 200 mg isavuconazole, as 372.6 mg isavuconazonium sulfate.1

hard capsule image

hard capsule

Each hard capsule contains 100 mg isavuconazole, as 186.3 mg isavuconazonium sulfate.1

For Medical Information, Drug Safety, and Product Complaints
Contact us by e-mail at basilea@druginfo.com or by phone at (UK) 08001413328

Reference

1. CRESEMBA Summary of Product Characteristics, Basilea Medical Ltd, 2015.